Business Context and Reporting Period
This Form 8-K, dated October 31, 2016, reports on Signal Genetics, Inc. (Signal). The filing details a material definitive agreement to merge with Miragen Therapeutics, Inc. (miRagen), a concurrent financing event, a reverse stock split, and amendments to debt instruments. The filing does not contain audited financial statements for a specific reporting period but focuses on transactional events occurring on October 31, 2016.
Key Financial Metrics and Transaction Terms
- Merger Consideration: Each outstanding share of miRagen common stock will convert into approximately 0.702 shares of Signal common stock (post-reverse split), subject to adjustment for Signal's net cash balance and additional miRagen share issuances.
- Post-Merger Ownership (Fully Diluted): Current Signal stockholders: ~4%; Current miRagen stockholders: ~69%; Concurrent financing investors: ~27%.
- Concurrent Financing: miRagen entered into a subscription agreement to raise approximately $40.7 million immediately prior to the merger closing.
- Debt Amendment: Signal amended a promissory note with Bennett LeBow to a principal of $1,045,000 with an 11% annual interest rate. The note is convertible into Signal common stock at $0.3594 per share (plus an 11% premium) prior to the merger effective time, subject to stockholder approval.
- Termination Fee: $300,000 plus reimbursement of specified expenses if the merger is terminated under certain circumstances.
- Asset Sale: Signal entered a non-binding letter of intent to sell MyPRS intellectual property assets. Proceeds are estimated to cover operating costs through the merger closing, effectively neutralizing the cash impact of the business.
Material Changes and Corporate Actions
- Reverse Stock Split: Signal announced a 1-for-15 reverse stock split effective November 4, 2016. Outstanding shares will decrease from approximately 11.1 million to 740,000.
- Corporate Name Change: Upon consummation of the merger, Signal will change its name to Miragen Therapeutics, Inc.
- Board Composition: The post-merger Board of Directors is expected to consist of eight members designated by miRagen.
- Equity Adjustments: All outstanding Signal stock options and restricted stock units (RSUs) will be cancelled without consideration. miRagen options and warrants will be assumed and adjusted.
- Executive Compensation: Vesting of RSUs for the CEO and CFO, and stock options for the CFO and Board members, was accelerated in full upon the business day prior to signing the merger agreement.
Guidance, Risks, and Contingencies
- Closing Conditions: The merger is subject to stockholder approval by both Signal and miRagen, satisfaction of conditions in the Merger Agreement, and the consummation of the concurrent financing.
- Support Agreements: Officers, directors, and stockholders controlling ~26% of Signal and ~80% of miRagen have entered into support agreements to vote in favor of the merger.
- Risks: Risks include failure to obtain stockholder approval, inability to consummate the MyPRS asset sale, uncertainty regarding clinical trial results for miRagen's product candidates, and regulatory approval processes.
- Forward-Looking Statements: The filing includes standard disclaimers regarding projections of future operations, capital adequacy, and the timing of the merger.
Key Facts for Investor Verification
- Verify the final exchange ratio and ownership percentages in the upcoming Form S-4 proxy statement/prospectus.
- Confirm the status of the $40.7 million concurrent financing and the definitive agreement for the MyPRS asset sale.
- Monitor the outcome of the stockholder votes required to approve the merger, the reverse split, and the debt conversion.
- Review the impact of the cancellation of existing Signal equity awards on employee retention and future compensation structures.
- Assess the combined company's cash position post-merger, considering the $40.7 million raise and the net cash adjustment to the exchange ratio.